- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04637750
Proton Pump Inhibitors (PPI): a Study to Improve Appropriate Prescriptions in the Elderly (LAPTOP-PPI)
April 9, 2024 updated by: Mario Negri Institute for Pharmacological Research
Evaluation of the Effectiveness of a Low-cost Informative Intervention to Improve the Appropriate Prescription of Proton Pump Inhibitors in Older People in Primary Care: a Cluster- Randomized Controlled Study
Proton Pump Inhibitors(PPIs) are the leading evidence-based therapy for upper gastrointestinal disorders and prevention of antiplatelet or non-steroidal anti-inflammatory drugs induced ulcer.
In Italy in 2015 nearly 3,5 millions of people were treated with PPI.
Despite the extensive literature regarding PPI adverse event, their inappropriate prescription rate is still increasing, and Campania and Lombardy region are at the highest level.
For this reason a cluster-randomised controlled trial will be performed, in order to evaluate if a low-cost informative intervention addressed to GPs is effective in improving PPIs prescription in older people.
The threshold will be defined according to the distribution of the rate of appropriate PPI prescriptions for a 6 months lag time starting 1 year before randomisation (baseline assessment).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A cluster-randomized controlled trial will be performed in order to evaluate if a low-cost informative intervention addressed to GPs is effective in improving PPIs prescription in older people.
All GPs of the Local Health Unit (LHU) of Caserta (southern Italy) and Bergamo (northern Italy) will be invited to participate to the study, because Caserta and Bergamo represent the areas with the highest level of inappropriate PPI prescription rate.
All GPs involved in the study will receive an invitation letter illustrating the study purpose and containing information about aggregated data on PPI prescriptions out of AIFA reimbursement criteria in Italy and their local area.
The GPs randomized to the intervention arm will also receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area.
They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI.
After 4 months GPs will also receive a patient-focused intervention leaflet and poster for patients about their medicines: what are the PPI and their possible side effects, nutritional and behavioral advices to prevent gastric and reflux problems and how to step down the treatment.
The appropriateness of PPI prescriptions will be defined according to the Italian Medicines Agency (AIFA) reimbursement rules (NOTA 1 and 48).
Study Type
Interventional
Enrollment (Actual)
800
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy, 20156
- Mario Negri Institute for Pharmacological Research
-
Napoli, Italy, 80131
- Università Degli Studi Di Napoli Federico Ii
-
-
Milan
-
Sesto San Giovanni, Milan, Italy, 20099
- IRCCS MultiMedica- MultiMedica Spa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
63 years and older (Older Adult)
Accepts Healthy Volunteers
No
Description
All the GPs in Caserta and Bergamo will be invited to participate to the study by the local authorities.
Inclusion Criteria for GPs patients:
- user of Proton Pump Inhibitors (at least one prescriptions in the period of interest)
- aged 65 or above
Exclusion Criteria:
- nursing homes residents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Educational intervention
Randomised GPs will receive the low cost informative intervention composed by a practitioner-focused letter plus leaflet for patients
|
The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area.
They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e.
gradual step down administration to avoid paradoxical effect).
|
No Intervention: Control group
GPs not receiving any informative intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short-term effectiveness
Time Frame: 6 months
|
Evaluate the short-term (6 months) effectiveness of a low-cost informative intervention in order to improve the appropriateness of prescription of PPI in older people in primary care in agreement with AIFA reimbursement rules by NHS in comparison to the daily clinical practice.
Generalised linear mixed model, with a proper link function, on the differences in the proportion of inappropriate prescriptions of PPIs after 6 months from intervention with respect to the baseline, will be used to assess the intervention effectiveness.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-term effectiveness
Time Frame: 12-18 months
|
Evaluation of the persistence of the effectiveness of the intervention in the long-term at 12 and 18 months.
Generalised linear mixed model, with a proper link function, on the differences in the proportion of inappropriate prescriptions of PPIs after 12-18 months from intervention with respect to the baseline, will be used to assess the intervention effectiveness.
|
12-18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of 'paradoxical effect'
Time Frame: 12-18 months
|
Evaluate the rate of 'paradoxical effect' (rebound acid hyper secretion) after gradual cessation of PPI therapy and the rate of the most frequent AEs (i.e.
pneumonia, bone fractures, bacterial enteric infections, diminished vitamin absorption, gastric and colon cancer, myocardial infarction and overall mortality ).
|
12-18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Carlotta Franchi, PhD, Mario Negri Institute for Pharmacological Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 10, 2019
Primary Completion (Actual)
March 14, 2023
Study Completion (Actual)
March 14, 2024
Study Registration Dates
First Submitted
November 9, 2020
First Submitted That Met QC Criteria
November 15, 2020
First Posted (Actual)
November 20, 2020
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
September 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- GR-2016-02361198
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proton Pump Inhibitor
-
Groupe Hospitalier Paris Saint JosephCompletedProton Pump InhibitorFrance
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Radboud University Medical CenterCompletedProton Pump Inhibitor | Inappropriate Drug Use | Discontinuation | E-healthNetherlands
-
Assiut UniversityUnknownProton Pump Inhibitor Allergy
-
Assiut UniversityUnknownProton Pump Inhibitor Allergy
-
Dr Abdurrahman Yurtaslan Ankara Oncology Training...CompletedProton Pump Inhibitor Adverse ReactionTurkey
-
Medical University of GrazCompletedPatients on Long-term Proton Pump Inhibitor TherapyAustria
-
American University of Beirut Medical CenterTakedaCompletedGERD | Proton Pump InhibitorLebanon
-
University of BariRecruitingProbiotic | Gastric Lesion | Proton Pump Inhibitor Adverse ReactionItaly
-
Kaohsiung Veterans General Hospital.CompletedBarrett Esophagus | Reflux | Proton Pump Inhibitor | Symptom
Clinical Trials on Educational intervention
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBacterial Infection | Clostridium DifficileUnited States
-
McGill University Health Centre/Research Institute...University of Manitoba; Sunnybrook Health Sciences Centre; University of Alberta and other collaboratorsCompletedPeptic Ulcer Hemorrhage
-
Universidad de GranadaNot yet recruitingAsthma | Allergy
-
Roswell Park Cancer InstituteCompletedCervical Cancer | Breast CancerUnited States
-
US Department of Veterans AffairsDuke UniversityCompletedAccidental FallsUnited States
-
Gary MorrowNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States
-
Azienda Unità Sanitaria Locale Reggio EmiliaCompletedMelanoma (Skin) | Educational ProblemsItaly
-
Goethe UniversityUnknownHealth Knowledge, Attitudes, PracticeGermany
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedBreast Cancer | LymphedemaUnited States
-
Claudia AristizábalUniversidad Nacional de Colombia; Universidad de Santander; Fundación Universitaria...Enrolling by invitationBurnout, Psychological | CaregiversColombia